Treatment-Related Adverse Effects

FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer

Fueled by trial-proven high response rates alongside favorable safety, the new approval pairs an oral HER2-selective inhibitor with its companion diagnostic